Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine

囊性纤维化的罕见突变:克服个性化医疗的障碍

基本信息

  • 批准号:
    9923749
  • 负责人:
  • 金额:
    $ 75.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

This project will focus on gaps in knowledge that must be overcome to advance precision, genotype-specific intervention for cystic fibrosis (CF). First, we will characterize disease-associated alleles, many of which are extremely rare, and have been assigned to an incorrect or incomplete mechanistic category. Other variants represent novel defects not evaluated previously. Our goal will be to elucidate limitations of the conventional diagnostic categories for disease-associated CF alleles, and to address modulator drug responsiveness (i.e., ‘theratype’) for a number of rare CFTR mutations that have not been previously tested in this manner. We will also provide examples of ways the recently solved CFTR cryo-EM structure can help define disease- associated mutations and their effects on CFTR folding (Aim 1). Our studies will provide cell systems for molecular phenotyping of alleles representing thousands of patients, and should be of value to the scientific community, clinicians, and patients with the disease. Second, new model systems are needed that predict in vivo benefit using drugs such as ivacaftor or Orkambi (which contains both ivacaftor and lumacaftor). As a test of emerging cell systems for this purpose, we will generate iPS lines corresponding to 20 of the CFTR variants profiled under Aim 1. Experiments such as these will provide a first evaluation of: 1) the extent to which iPS cells can be used effectively as polarized monolayers according to the best available and innovative protocols developed by our laboratory and others, 2) whether these model systems exhibit detectable modulator response in vitro, 3) whether iPS cells are similar in molecular phenotype to widely used (FRT) cell models encoding the same mutations for this purpose, 4) usefulness of leading edge gene editing technologies in iPS cells to produce first-line systems, and 5) practical features of iPS technology vis-à-vis personalized therapeutics, including the extent to which an individual patient sample can be expanded effectively, durability of CFTR expression, function in vitro, stability of monolayers developed in this manner (Aim 2), etc. Finally, we will take up the challenge to establish the practical usefulness of our work by facilitating a new intervention in CF patients carrying the P67L/F508del genotype, a case study emblematic of hundreds of other CFTR variants. We have a compelling body of data indicating that P67L patients will benefit significantly from a drug such as Orkambi. Aim 3 will formally pursue this assertion in a clinical setting by directly testing human subjects with this very rare allele. If successful as predicted, a group of patients who currently have no effective modulator therapy will directly benefit. Moreover, because we believe it is likely that iPS cells will recapitulate clinical efficacy, the data is intended to help establish an in vitro surrogate that will improve drug access and precision therapeutics for a population of CF patients carrying rare variants other than P67L.
该项目将侧重于必须克服的知识差距,以提高精确度,基因型特异性 囊性纤维化(CF)的治疗。首先,我们将描述疾病相关的等位基因,其中许多是 非常罕见,并已被分配到一个不正确或不完整的机械类别。其他变体 代表之前未评估的新缺陷。我们的目标将是阐明传统的限制, 疾病相关CF等位基因的诊断类别,并解决调节剂药物反应性(即, “治疗型”),用于许多以前未以这种方式测试的罕见CFTR突变。我们将 还提供了最近解决的CFTR cryo-EM结构可以帮助定义疾病的方法的例子- 相关突变及其对CFTR折叠的影响(目的1)。我们的研究将提供细胞系统, 代表数千名患者的等位基因的分子表型,应该对科学研究有价值。 社区、临床医生和患者。第二,需要新的模型系统, 使用药物如ivacaftor或Orkambi(其含有ivacaftor和lumacaftor两者)的体内益处。作为测试 为了这个目的,我们将产生对应于20个CFTR变体的iPS系 目标1下的配置文件。这样的实验将提供以下初步评估:1)iPS在多大程度上 根据最好的可用的和创新的方案 2)这些模型系统是否表现出可检测的调制器 3)iPS细胞是否在分子表型上与广泛使用的(FRT)细胞模型相似 编码相同的突变,4)尖端基因编辑技术在iPS中的有用性 细胞生产一线系统,以及5)iPS技术的实用功能与个性化 治疗,包括个体患者样本可以有效扩增的程度,耐久性 CFTR的表达,体外功能,以这种方式开发的单层的稳定性(目的2)等。最后,我们 我们将迎接挑战,通过促进新的干预措施, 携带P67 L/F508 del基因型的CF患者,一项象征数百种其他CFTR的病例研究 变体。我们有令人信服的数据表明,P67L患者将从药物中显著获益。 例如Orkambi。Aim 3将在临床环境中通过直接测试人类 有这种罕见等位基因的人如果成功的预测,一组病人谁目前没有有效的 调节剂治疗将直接受益。此外,因为我们相信iPS细胞很可能会重演 临床疗效,这些数据旨在帮助建立一个体外替代品,将改善药物的获取, 用于携带P67L以外的罕见变体的CF患者群体的精确治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian R. Davis其他文献

432 - M2 Macrophages are Linked with Pyloric Fibrosis in Patients with Gastroparesis Symptoms
  • DOI:
    10.1016/s0016-5085(17)30681-9
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Richard W. McCallum;Alireza Torabi;Mohammad Bashashati;Daniel Welder;Irene Sarosiek;Jesus R. Diaz;Brian R. Davis;Dolgor Baatar
  • 通讯作者:
    Dolgor Baatar
Cross cultural examination of parents’ expectations for their children’s development of self
跨文化审视父母对孩子自我发展的期望
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Brian R. Davis;& Yuki Shimizu;Yuki Shimizu;岩田美保;西村多久磨・鈴木高志・村上達也・中山伸一・櫻井茂男;Sawa Senzaki & Yuki Shimizu
  • 通讯作者:
    Sawa Senzaki & Yuki Shimizu
Sa1550 - Long Term Effect of Chronic Neurostimulation in Combination with Pyroplasty and Role of Antral Interstitial Cells of Cajal: Experience from One Academic Center
  • DOI:
    10.1016/s0016-5085(18)31374-x
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Irene Sarosiek;Karina Espino;Natalia Vega;Richard W. McCallum;Brian R. Davis;Mohammad Bashashati;Eric Yeager;Tamis Bright
  • 通讯作者:
    Tamis Bright
Sa1123: DIFFERENTIAL EXPRESSION OF MACROPHAGES AND INFLAMMATORY MEDIATORS IN GASTRIC ANTRAL SMOOTH MUSCLE OF PATIENTS WITH IDIOPATHIC GASTROPARESIS COMPARED TO DIABETIC ETIOLOGY
  • DOI:
    10.1016/s0016-5085(22)60750-9
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Vikram Thakur;Brian R. Davis;Irene Sarosiek;Richard W. McCallum;Sourav Roy;Munmun Chattopadhyay
  • 通讯作者:
    Munmun Chattopadhyay
Su1737 LESSONS LEARNED FROM 8 YEARS OF FOLLOW UP OF DRUG REFRACTORY GASTROPARETIC PATIENTS WHO UNDERWENT SIMULTANEOUS IMPLANTATION OF GASTRIC ELECTRICAL STIMULATION SYSTEM AND SURGICAL PYLOROPLASTY.
  • DOI:
    10.1016/s0016-5085(20)32265-4
  • 发表时间:
    2020-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Irene Sarosiek;Brian R. Davis;Karina Espino;Jerzy Sarosiek;Natalia Vega;Kenneth A. Dominguez;Jesus R. Diaz;Richard W. McCallum
  • 通讯作者:
    Richard W. McCallum

Brian R. Davis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian R. Davis', 18)}}的其他基金

Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine
囊性纤维化的罕见突变:克服个性化医疗的障碍
  • 批准号:
    10388245
  • 财政年份:
    2018
  • 资助金额:
    $ 75.71万
  • 项目类别:
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine
囊性纤维化的罕见突变:克服个性化医疗的障碍
  • 批准号:
    9754239
  • 财政年份:
    2018
  • 资助金额:
    $ 75.71万
  • 项目类别:
Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicine
囊性纤维化的罕见突变:克服个性化医疗的障碍
  • 批准号:
    10187642
  • 财政年份:
    2018
  • 资助金额:
    $ 75.71万
  • 项目类别:
Gene corrected iPS-derived lung cells for therapy of inherited lung diseases
基因校正的 iPS 衍生肺细胞用于治疗遗传性肺病
  • 批准号:
    7814962
  • 财政年份:
    2010
  • 资助金额:
    $ 75.71万
  • 项目类别:
Somatic Mosaicism in the Wiskott-Aldrich Syndrome
威斯科特-奥尔德里奇综合征中的体细胞镶嵌
  • 批准号:
    7864037
  • 财政年份:
    2009
  • 资助金额:
    $ 75.71万
  • 项目类别:
Somatic Mosaicism in the Wiskott-Aldrich Syndrome
威斯科特-奥尔德里奇综合征中的体细胞镶嵌
  • 批准号:
    7640171
  • 财政年份:
    2009
  • 资助金额:
    $ 75.71万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 75.71万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了